| Literature DB >> 36225628 |
Xuyong Wei1,2, Wentao Xie1,3,2, Weiwei Yin4, Mengfan Yang1,3,2, Abdul Rehman Khan1,3,2, Renyi Su1,2, Wenzhi Shu1,2, Binhua Pan1,3,2, Guanghan Fan1,3,2, Kun Wang1,3,2, Fan Yang1,2, Di Lu1,2, Changbiao Li1,2, Linhui Pan1,2, Beini Cen1,2, Haiyang Xie3,2, Li Zhuang5, Shusen Zheng3,2,5, Xun Zeng6,7, Wei Chen4,8,9,7, Xiao Xu1,2,10.
Abstract
Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is a marker of poor prognosis. However, the reliable biomarkers of post-LT HCC recurrence remain to be identified. In this study, serial peripheral blood samples from the LT recipients with and without HCC recurrence were collected at five time points. Single-cell mass cytomertry (CyTOF) was utilized for the in-depth analysis of peripheral blood monocellular cells (PBMCs). CyTOF analysis showed that at 3 weeks post-LT, the activated immune cell population was increased, while the fraction of immune cells with suppressive functions (myeloid-derived suppressive cells) was reduced. The post-LT immune composition in patients with LT for HCC was enormously different from that in patients with LT for causes other than HCC. Furthermore, at 3 weeks after LT, compared with patients without recurrence, the patients with HCC recurrences were high in two subsets of T cells: CD57+ HLA-DR+ CD8+ and CD28+γδ. The CD57+ HLA-DR+ CD8+ T cells presented high levels of perforin, granzyme B, and Ki-67 and displayed a highly cytotoxic and proliferative phenotype, while the CD28+γδ T cells had reduced levels of IFN-γ and, hence, were less activated compared to CD28- cells. Based on these findings, we concluded that analyzing the PBMCs of LT recipients by CyTOF can predict the post-LT HCC recurrence. The distinct immune features can stratify patients with the risk of HCC recurrence at 3 weeks after LT, which will help clinician in further management plan and improve the prognosis of patients. AJCREntities:
Keywords: Hepatocellular carcinoma; liver transplantation; mass cytometry
Year: 2022 PMID: 36225628 PMCID: PMC9548010
Source DB: PubMed Journal: Am J Cancer Res ISSN: 2156-6976 Impact factor: 5.942